(OLMA) Olema Pharmaceuticals - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 1.403m USD | Total Return: 296.6% in 12m

Cancer Therapies, Drug Development, Clinical Trials
Total Rating 51
Safety 66
Buy Signal -0.27
Biotechnology
Industry Rotation: -8.0
Market Cap: 1.40B
Avg Turnover: 19.0M USD
ATR: 7.06%
Peers RS (IBD): 81.8
Risk 5d forecast
Volatility90.0%
Rel. Tail Risk-15.8%
Reward TTM
Sharpe Ratio1.53
Alpha416.73
Character TTM
Beta0.151
Beta Downside-3.218
Drawdowns 3y
Max DD82.15%
CAGR/Max DD0.79
EPS (Earnings per Share) EPS (Earnings per Share) of OLMA over the last years for every Quarter: "2021-03": -0.39, "2021-06": -0.42, "2021-09": -0.45, "2021-12": -0.54, "2022-03": -0.58, "2022-06": -0.82, "2022-09": -0.57, "2022-12": -0.65, "2023-03": -0.7, "2023-06": -0.49, "2023-09": -0.48, "2023-12": -0.49, "2024-03": -0.56, "2024-06": -0.54, "2024-09": -0.6, "2024-12": -0.51, "2025-03": -0.36, "2025-06": -0.51, "2025-09": -0.49, "2025-12": -0.5044, "2026-03": 0,
EPS CAGR: 113.13%
EPS Trend: 67.7%
Last SUE: 1.99
Qual. Beats: 1
Revenue Revenue of OLMA over the last years for every Quarter: 2021-03: 0, 2021-06: 0, 2021-09: 0, 2021-12: 0, 2022-03: 0, 2022-06: 0, 2022-09: 0, 2022-12: 0, 2023-03: 0, 2023-06: 0, 2023-09: 0, 2023-12: 1.884, 2024-03: 0, 2024-06: 0, 2024-09: 0, 2024-12: 0.364, 2025-03: 0, 2025-06: 0, 2025-09: 0, 2025-12: 0, 2026-03: null,
Rev. CAGR: 0.00%
Rev. Trend: 2.2%
Last SUE: 0.00
Qual. Beats: 0

Warnings

Share dilution 47.5% YoY - potential capital distress

Altman Z'' -11.76 < 1.0 - financial distress zone

Volatile

Tailwinds

No distinct edge detected

Description: OLMA Olema Pharmaceuticals

Olema Pharmaceuticals is a clinical-stage biopharmaceutical company headquartered in San Francisco, focused on the discovery and development of targeted therapies for women’s cancers. As a pre-revenue biotechnology firm, its business model centers on advancing proprietary small-molecule drugs through regulatory approval, specifically targeting endocrine resistance mechanisms in breast cancer.

The company’s lead product candidate is palazestrant, a complete estrogen receptor antagonist and selective ER degrader (CERAN/SERD). Palazestrant is currently undergoing a pivotal Phase 3 trial (OPERA-01) as a monotherapy for second- and third-line treatment of ER+/HER2- metastatic breast cancer. Olema is also evaluating the drug in Phase 1/2 trials in combination with CDK4/6, PI3Kα, and mTOR inhibitors. Beyond its lead asset, the company is developing OP-3136, a KAT6 inhibitor currently in Phase 1 studies for metastatic breast cancer and other malignancies.

For a deeper assessment of Olemas clinical milestones and financial metrics, you can research further on ValueRay.

Headlines to Watch Out For
  • Palazestrant Phase 3 trial results impact stock
  • Regulatory approval for palazestrant drives revenue
  • Clinical trial failures increase development costs
  • Competition in breast cancer therapies affects market share
Piotroski VR‑10 (Strict) 0.0
Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM)
FCF/TA: -0.28 > 0.02 and ΔFCF/TA -4.33 > 1.0
NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev)
CFO/TA -0.28 > 3% & CFO -146.7m > Net Income -162.5m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 9.95 > 1.5 & < 3
Outstanding Shares: last quarter (91.3m) vs 12m ago 55.45% < -2%
Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin)
Asset Turnover: 0.0% > 50% (prev 0.08%; Δ -0.08% > 0%)
Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM)
Altman Z'' -11.76
A: 0.87 (Total Current Assets 515.5m - Total Current Liabilities 51.8m) / Total Assets 533.4m
B: -1.12 (Retained Earnings -597.6m / Total Assets 533.4m)
C: -0.36 (EBIT TTM -175.0m / Avg Total Assets 492.2m)
D: -10.88 (Book Value of Equity -596.9m / Total Liabilities 54.9m)
Altman-Z'' Score: -11.76 = D
What is the price of OLMA shares? As of April 13, 2026, the stock is trading at USD 16.10 with a total of 1,211,458 shares traded.
Over the past week, the price has changed by +6.13%, over one month by +7.98%, over three months by -44.08% and over the past year by +296.55%.
Is OLMA a buy, sell or hold? Olema Pharmaceuticals has received a consensus analysts rating of 4.63. Therefore, it is recommended to buy OLMA.
  • StrongBuy: 5
  • Buy: 3
  • Hold: 0
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the OLMA price?
Analysts Target Price 43 167.1%
Olema Pharmaceuticals (OLMA) - Fundamental Data Overview as of 12 April 2026
P/B = 2.9322
Revenue TTM = 0.0 USD
EBIT TTM = -175.0m USD
EBITDA TTM = -174.5m USD
Long Term Debt = 3.00m USD (from longTermDebt, last quarter)
Short Term Debt = 1.12m USD (from shortTermDebt, last quarter)
Debt = 4.12m USD (corrected: LT Debt 3.00m + ST Debt 1.12m)
Net Debt = -501.3m USD (recalculated: Debt 4.12m - CCE 505.4m)
Enterprise Value = 901.9m USD (1.40b + Debt 4.12m - CCE 505.4m)
 Interest Coverage Ratio = unknown (Ebit TTM -175.0m / Interest Expense TTM 0.0)
 EV/FCF = -6.15x (Enterprise Value 901.9m / FCF TTM -146.7m)
FCF Yield = -16.27% (FCF TTM -146.7m / Enterprise Value 901.9m)
 FCF Margin = unknown (Revenue TTM is 0 or missing)
 Net Margin = unknown
 Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 315k) / Revenue TTM)
 Tobins Q-Ratio = 1.69 (Enterprise Value 901.9m / Total Assets 533.4m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 4.12m)
Taxrate = 21.0% (US default 21%)
NOPAT = -138.3m (EBIT -175.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 9.95 (Total Current Assets 515.5m / Total Current Liabilities 51.8m)
Debt / Equity = 0.01 (Debt 4.12m / totalStockholderEquity, last quarter 478.6m)
 Debt / EBITDA = 2.87 (negative EBITDA) (Net Debt -501.3m / EBITDA -174.5m)
 Debt / FCF = 3.42 (negative FCF - burning cash) (Net Debt -501.3m / FCF TTM -146.7m)
 Total Stockholder Equity = 378.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -33.00% (Net Income -162.5m / Total Assets 533.4m)
RoE = -42.90% (Net Income TTM -162.5m / Total Stockholder Equity 378.7m)
RoCE = -45.86% (EBIT -175.0m / Capital Employed (Equity 378.7m + L.T.Debt 3.00m))
 RoIC = -36.30% (negative operating profit) (NOPAT -138.3m / Invested Capital 380.9m)
 WACC = 6.49% (E(1.40b)/V(1.41b) * Re(6.51%) + D(4.12m)/V(1.41b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 6.51% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares Correlation 3-Years: 100.0 | Cagr: 39.04%
 [DCF] Fair Price = unknown (Cash Flow -146.7m)
 EPS Correlation: 67.72 | EPS CAGR: 113.1% | SUE: 1.99 | # QB: 1
Revenue Correlation: 2.19 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-0.56 | Chg7d=+0.000 | Chg30d=-0.000 | Revisions Net=+1 | Analysts=10
EPS current Year (2026-12-31): EPS=-2.29 | Chg7d=-0.004 | Chg30d=+0.023 | Revisions Net=+0 | Growth EPS=-22.3% | Growth Revenue=+0.0%
EPS next Year (2027-12-31): EPS=-2.54 | Chg7d=-0.051 | Chg30d=+0.026 | Revisions Net=+0 | Growth EPS=-11.2% | Growth Revenue=+1031.7%
[Analyst] Revisions Ratio: +0.20 (3 Up / 2 Down within 30d for Next Quarter)
External Resources
Dataroma Stockcircle